Wells Fargo & Company Oncorus, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.28 - $0.45 $0 - $0	2 Added 1.5%	135 $0
Q4 2022 Feb 13, 2023	BUY	$0.24 - $0.76 $0 - $3	4 Added 3.1%	133 $0
Q3 2022 Nov 14, 2022	BUY	$0.85 - $1.65 $13 - $26	16 Added 14.16%	129 $0
Q2 2022 Aug 12, 2022	SELL	$1.04 - $1.86 $1,750 - $3,130	-1,683 Reduced 93.71%	113 $0
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $10,412 - $40,638	-7,231 Reduced 80.1%	1,796 $3,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $45,405 - $104,984	9,027 New	9,027 $47,000
Q3 2021 Nov 15, 2021	SELL	$9.29 - $14.27 $1,839 - $2,825	-198 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.3 - $17.3 $28,728 - $37,368	-2,160 Reduced 91.6%	198 $3,000
Q1 2021 May 13, 2021	SELL	$11.89 - $35.55 $12,936 - $38,678	-1,088 Reduced 31.57%	2,358 $33,000
Q4 2020 Feb 09, 2021	BUY	$15.0 - $35.15 $51,690 - $121,126	3,446 New	3,446 $111,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.